Insider trading

Period: 120 months Stock: ABUS + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

21 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

21 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

21 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

21 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
21 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
21 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

21 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
4 Feb 2025
McElhaugh Michael J. Interim President & CEO
Sold on a plan
$78.10K 23,790 at 3.28
1.6%
Planned (10b5-1)
4 Feb 2025
HASTINGS DAVID C Chief Financial Officer
Sold on a plan
$72.83K 22,183 at 3.28
12.2%
Planned (10b5-1)
4 Feb 2025
Sims Karen Chief Medical Officer
Sold on a plan
$63.52K 19,348 at 3.28
15.4%
Planned (10b5-1)
4 Feb 2025
Naftzger J. Christopher General Counsel and CCO
Sold on a plan
$37.21K 11,333 at 3.28
11.6%
Planned (10b5-1)
14 Aug 2024
Sold at will
$32.64K 8,846 at 3.69
16.1%
Not planned
2 Feb 2024
McElhaugh Michael J. Interim President & CEO
Sold on a plan
$23.50K 10,164 at 2.31
0.7%
Planned (10b5-1)
2 Feb 2024
Sofia Michael J. Chief Scientific Officer
Sold on a plan
$23.08K 9,982 at 2.31
0.7%
Planned (10b5-1)
2 Feb 2024
HASTINGS DAVID C Chief Financial Officer
Sold on a plan
$22.18K 9,593 at 2.31
5.0%
Planned (10b5-1)
2 Feb 2024
Sims Karen Chief Medical Officer
Sold on a plan
$10.08K 4,358 at 2.31
3.4%
Planned (10b5-1)
1 Dec 2021
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$1.02M 200,000 at 5.09
13.3%
9 Feb 2021
McElhaugh Michael J. Chief Business Officer
Sold, plan not stated
$100.00K 20,000 at 5.00
1.5%
14 Dec 2020
McElhaugh Michael J. Chief Business Officer
Sold, plan not stated 2×
$200.03K 40,000 at 5.00
2.9%
23 Jul 2020
McElhaugh Michael J. Chief Business Officer
Sold, plan not stated
$100.20K 20,000 at 5.01
1.4%
13 Aug 2018
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$40.44K 4,250 at 9.51
0.3%
11 Jul 2018
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$100.00K 10,000 at 10.00
0.7%
9 Jul 2018
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$89.06K 10,000 at 8.91
0.7%
6 Jul 2018
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$84.50K 10,000 at 8.45
0.7%
5 Jul 2018
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$84.00K 10,000 at 8.40
0.6%
3 Jul 2018
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$80.00K 10,000 at 8.00
0.6%
3 Oct 2017
Sofia Michael J. Chief Scientific Officer
Sold, plan not stated
$80.00K 10,000 at 8.00
0.6%
15 Aug 2017
Sofia Michael J. Chief Scientific Officer · indirect
Sold, plan not stated 2×
$111.00K 30,000 at 3.70
14.9%
Showing 1–21 of 21.